Publisher
source

Medicines Evaluation Board

PhD in Regulatory and Access Pathways for Leukodystrophy Medicines Evaluation Board in Netherlands

Degree Level

PhD

Field of study

Biomedical Engineering

Funding

MSCA Doctoral Network PhD position. The candidate will be employed by the Medicines Evaluation Board in Utrecht and embedded in the POLARIS consortium. The post includes network training, secondments, and research experience; no stipend amount is stated in the post.

Deadline

Oct 5, 2026

Country flag

Country

Netherlands

University

Medicines Evaluation Board

Social connections

How do I apply for this?

Sign in for free to reveal details, requirements, and source links.

Apply for this position

Keywords

Biomedical Engineering
Biology
Health Economics
Medical Science
Pharmacy
Salud Pública
Regulatory Science
Law
Reimbursement
Rare Disease
Patient-reported Outcome

Suggested positions

About this position

POLARIS is a European Marie Skłodowska-Curie Doctoral Network focused on accelerating therapy development for leukodystrophies, rare genetic disorders affecting the brain’s white matter.

This PhD position is centered on regulatory science, orphan medicines, advanced therapy medicinal products (ATMPs), patient-reported outcomes, and cross-border access and reimbursement for innovative therapies in rare diseases.

The recruiting organisation is the Medicines Evaluation Board (MEB) in Utrecht, Netherlands. The candidate will be employed by the MEB and embedded in the POLARIS consortium, with supervision by Dr Marjon Pasmooij. The project is linked to the Amsterdam Leukodystrophy Center at Amsterdam UMC and the platform Medicijn voor de Maatschappij, with secondments at University Hospital Tübingen through the European Reference Network for Rare Neurological Diseases (ERN-RND).

Research activities include regulatory document analysis, expert interviews, and case studies on the development and accessibility of therapies for rare diseases. The work addresses regulatory, organisational, and scientific factors influencing orphan medicine development in academic settings; requirements for small-scale manufacturing and quality control of ATMPs; patient-reported outcomes relevant to leukodystrophy therapies; and European access/reimbursement pathways.

This is a PhD opening within an international, interdisciplinary doctoral network that includes academic research, industry-based preclinical development, secondments, and transferable-skills training. The post is based in the Netherlands.

Deadline: 5 October 2026.

Apply via AcademicTransfer using the link in the post.

Funding details

MSCA Doctoral Network PhD position. The candidate will be employed by the Medicines Evaluation Board in Utrecht and embedded in the POLARIS consortium. The post includes network training, secondments, and research experience; no stipend amount is stated in the post.

What's required

Applicants should be interested in regulatory science, rare diseases, orphan medicines, advanced therapy medicinal products, patient-reported outcomes, and cross-border access/reimbursement. The project uses regulatory document analysis, expert interviews, and case studies, so analytical and qualitative research skills are relevant. The post is a PhD position within the POLARIS doctoral network and involves secondments in Utrecht, Amsterdam, and Tübingen.

How to apply

Apply via the AcademicTransfer link provided in the post. Review the full vacancy details and submit your application through the portal before the deadline. Check the posting for any additional documents or eligibility instructions.

More information can be found here

Ask ApplyKite AI

Start chatting
Can you summarize this position?
What qualifications are required for this position?
How should I prepare my application?